Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-896-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Celsion (NASDAQ:CLSN) Frequently Asked Questions
What is Celsion's stock symbol?
Celsion trades on the NASDAQ under the ticker symbol "CLSN."
When did Celsion's stock split? How did Celsion's stock split work?
Celsion shares reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.
How were Celsion's earnings last quarter?
Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 1,489.20% and a negative return on equity of 53.40%. View Celsion's Earnings History.
When is Celsion's next earnings date?
What price target have analysts set for CLSN?
2 brokerages have issued 12 month target prices for Celsion's shares. Their predictions range from $9.00 to $9.00. On average, they expect Celsion's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 417.2% from the stock's current price. View Analyst Price Targets for Celsion.
What is the consensus analysts' recommendation for Celsion?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.
Has Celsion been receiving favorable news coverage?
Press coverage about CLSN stock has trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celsion earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Celsion.
Who are some of Celsion's key competitors?
Some companies that are related to Celsion include Kala Pharmaceuticals (KALA), MEI Pharma (MEIP), Aptinyx (APTX), Chimerix (CMRX), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Correvio Pharma (CORV), Menlo Therapeutics (MNLO), Chembio Diagnostics (CEMI), OASMIA PHARMACE/ADR (OASM), Corvus Pharmaceuticals (CRVS), Eton Pharmaceuticals (ETON), Savara (SVRA), Relmada Therapeutics (RLMD) and Sesen Bio (SESN).
What other stocks do shareholders of Celsion own?
Who are Celsion's key executives?
Celsion's management team includes the folowing people:
- Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)
- Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)
- Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)
- Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)
- Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61)
Who are Celsion's major shareholders?
Celsion's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.44%) and BlackRock Inc. (0.71%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Institutional Ownership Trends for Celsion.
Which institutional investors are buying Celsion stock?
CLSN stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and BlackRock Inc.. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Jeffrey Wayne Church, Michael H Tardugno and Robert W Hooper. View Insider Buying and Selling for Celsion.
How do I buy shares of Celsion?
Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Celsion's stock price today?
One share of CLSN stock can currently be purchased for approximately $1.74.
How big of a company is Celsion?
Celsion has a market capitalization of $37.22 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-11,880,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Celsion employs 29 workers across the globe.View Additional Information About Celsion.
What is Celsion's official website?
How can I contact Celsion?
Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]
MarketBeat Community Rating for Celsion (NASDAQ CLSN)
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
